About: BI 224436

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.

Property Value
dbo:abstract
  • BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program. Clinical trials were abandoned in advance of Phase 1. (en)
dbo:casNumber
  • 1155419-89-8
dbo:fdaUniiCode
  • 99A996378Y
dbo:pubchem
  • 66561902
dbo:thumbnail
dbo:wikiPageID
  • 33394088 (xsd:integer)
dbo:wikiPageLength
  • 4384 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1123268484 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:c
  • 27 (xsd:integer)
dbp:casNumber
  • 1155419 (xsd:integer)
dbp:chemspiderid
  • 32698770 (xsd:integer)
dbp:eliminationHalfLife
  • 25200.0
dbp:h
  • 26 (xsd:integer)
dbp:iupacName
  • -[4--2-methyl-3-quinolinyl] [oxy]acetic acid (en)
dbp:legalStatus
  • Investigational (en)
dbp:n
  • 2 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 66561902 (xsd:integer)
dbp:smiles
  • CC1=NC2=CC=CC=C2CC3=C4C5=COCCC5=CC=N4 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • MIXIIJCBELCMCZ-VWLOTQADSA-N (en)
dbp:unii
  • 99 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program. (en)
rdfs:label
  • BI 224436 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License